Vertex Pharmaceuticals Reports Narrower But Still Negative Q4 Loss

Vertex Pharmaceuticals (VRTX) reported a narrower but still negative net loss of $287.9 million for the fourth quarter ended December 31, 2025, compared to $331.7 million in the same period of 2024. The company attributed the improvement to lower R&D expenses and a reduction in newsgroups-related payments, though revenue remained flat at $1.22 billion. CEO Dr. Andrew Ankri stated the company is focused on accelerating the development of gene-editing therapies and maintaining a strong pipeline.